Epigenetic Enzyme Expression

The phrase 'epigenetic enzyme expression' describes the cellular levels and activities of enzymes that mediate epigenetic modifications—including DNA methyltransferases, histone deacetylases, histone methyltransferases, and others—which collectively regulate chromatin structure and gene transcription without altering the DNA sequence. Aberrant expression or dysregulation of these enzymes is implicated in diverse pathologies such as cancer, metabolic, neurological, and inflammatory diseases. These enzymes are recognized as a major class of drug targets, with several epigenetic drugs (notably DNMT and HDAC inhibitors) approved for clinical use, particularly in cancer. However, 'epigenetic enzyme expression' is not the name of a specific molecular target, but instead refers to the general process and its associated enzyme families[1][2][6][8]. Context and Limitations: "Epigenetic Enzyme Expression" is not a standardized name for any individual protein, receptor, or therapeutic target; instead, it reflects a broad and heterogeneous group of enzymes involved in chromatin and DNA modifications[2][6]. Many individual enzymes within this class (such as DNMT1, EZH2, or HDAC1) are recognized as distinct drug targets, but the umbrella term does not denote a specific molecule. To generate structured drug target information, it is necessary to specify the exact enzyme (e.g., "DNA methyltransferase 1," "EZH2," or "Bromodomain-containing protein 4")[2][6][8].

Other names

Epigenetic enzymesEpigenetic regulatorsEpigenetic modifying enzymes

Inhibition of DNA methyltransferase (hypomethylation of DNA); Inhibition of histone deacetylase (increased histone acetylation); Inhibition of histone methyltransferase (blockage of methylation); Inhibition of bromodomain recognition (blocking reader domains); Disruption of non-coding RNA interaction